Antagonism of VIP-stimulated cyclic AMP formation in chick brain

Journal of Molecular Neuroscience

Volumn 20, Issue 2, 2003, Pages 163-171

  Nowak, Jerzy Z ^a   Sedkowska, Paulina ^a   Zawilska, Jolanta B ^a   Gozes, Illana ^b   Brenneman, Douglas E ^c  

^a POLISH ACADEMY OF SCIENCES   (Poland)

^b TEL AVIV UNIVERSITY   (Israel)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Chick cerebral cortex; Cyclic AMP (cAMP); PACAP; PACAP antagonist; VIP; VIP antagonist

Indexed keywords

A 6938; A 9808; CYCLIC AMP; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE[6-27]; NEUROTENSIN[6-11]; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE[6-28];

ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BRAIN CORTEX; DRUG ACTIVITY; DRUG RECEPTOR BINDING; NONHUMAN; RECEPTOR BLOCKING; REGULATORY MECHANISM;

ANIMALS; CEREBRAL CORTEX; CHICKENS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MALE; NEUROPEPTIDES; PEPTIDE FRAGMENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; REACTION TIME; VASOACTIVE INTESTINAL PEPTIDE;

ANIMALIA; GALLUS GALLUS; MAMMALIA;

EID: 0037942717     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:20:2:163     Document Type: Article

References (32)

1. Arimura A. (1998) Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Japan J. Physiol. 48, 301-331.
2. Delgado M., Abad C., Martinez C., Juarranz M. G., Arranz A., Gomari R. P., and Leceta J. (2002) Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J. Mol. Med. 80, 16-24.
3. Fishbein V. A., Coy D. H., Hocart S. J., Jiang N. Y., Mrozinski J. E., Mantey S. A., and Jansen R. T. (1994) A chimeric VIP-PACAP analogue but not VIP pseudopeptides function as VIP receptor antagonists. Peptides 15, 95-100.
4. Gourlet P., De Neef P., Cnudde J., Waelbroeck M., and Robberecht P. (1997) In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides 18, 1555-1560.
5. Gourlet P., Vandermeers A., Vandermeers-Piret M. C., De Neef P., and Robberecht P. (1996) Addition of the (28-38) peptide sequence of PACAP to the VIP sequence modifies peptide selectivity and efficacy. Int. J. Protein Res. 48, 391-396.
6. Gozes I. and Brenneman D. E. (1989) VIP: molecular biology and neurobiological function. Mol. Neurobiol. 3, 201-236.
7. Gozes I., Fridkin M., Hill J. M., and Brenneman D. E. (1999) Pharmacological VIP: prospects and problems. Curr. Med. Chem. 6, 1019-1034.
8. Gozes I., Meltzer E., Rubinrout S., Brenneman D. E., and Fridkin M. (1989) Vasoactive intestinal peptides potentiates sexual behavior: inhibition by novel antagonist. Endocrinology 125, 2945-2949.
9. Gozes I., McCune S. K., Jacobson L., Warren D., Moody T. W., Fridkin M., and Brenneman D. E. (1991) An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J. Pharmacol. Exp. Ther. 257, 959-966.
10. Harmar A. J., Arimura A., Gozes I., et al. (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev. 50, 265-270.
11. Kansaku N., Shimada K., Ohkubo T., Saito N., Suzuki T., Matsuda Y., and Zadworny D. (2001) Molecular cloning of chicken vasoactive intestinal polypeptide receptor complementary DNA, tissue distribution and chromosomal localization. Biol. Reprod. 64, 1575-1581.
12. Klimaschewski L. (1997) VIP-a very important peptide in the sympathetic nervous system? Anat. Embryol. 196, 269-277.
13. Laburthe M., Couvineau A., and Voisin T. (1998) Receptors for peptides of the VIP/PACAP and PYY/NPY/PP families, in Gastrointestinal Endocrinology, Greeley G. H., ed., Humana, Totowa, NJ, pp. 125-157.
14. Muller J. M., Lelievre V., Becq-Giraudon L., and Meunier A. C. (1995) VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment. Mol. Neurobiol. 10, 115-134.
15. Nilsson A. (1974) Isolation, amino acid composition and terminal amino acid residues of the vasoactive octacosapeptide from chicken intestine. Partial purification of chicken secretin. FEBS Lett. 47, 284-289.
16. Nowak J. Z. (2001) PACAP in the avian brain: receptors and possible functions. Pol. J. Pharmacol. 53 (Suppl.), 26-27.
17. Nowak J. Z. and Kuba K. (2001a) Vasoactive intestinal peptide-stimulated adenosine 3′,5′-cyclic monophosphate formation in cerebral cortex and hypothalamus of chick and rat: comparison of the chicken and mammalian peptide. Neurosci. Lett. 297, 93-96.
18. Nowak J. Z. and Kuba K. (2001b) PACAP-stimulated formation of cyclic AMP in the avian brain. J. Mol. Neurosci. 16(Suppl.), 77-78.
19. Nowak J. Z. and Zawilska J. B. (2003) PACAP in avians: origin, occurrence, and receptors - pharmacological and functional considerations. Curr. Pharm. Des. 6, 467-481.
20. Nowak J. Z., Kuba K., and Zawilska J. B. (1999a) PACAP-induced formation of cyclic AMP in the chicken brain: regional variations and the effect of melatonin. Brain Res. 830, 195-199.
21. Nowak J. Z., Kuba K., and Zawilska J. B. (1999b) Stimulatory effect of pituitary adenylate cyclase-activating polypeptide (PACAP) on cyclic AMP formation in the hypothalamus and cerebral cortex of four avians and rat. Pol. J. Pharmacol. 51, 87-91.
22. 17]VIP. Am. J. Physiol. 250 (Gastrointest. Liver Physiol. 13), G553-G557.
23. Robberecht P., Gourlet P., De Neef P., Woussen-Colle M. C., Vandermeers-Piret M. C., Vandermeers A., and Chrostophe J. (1992) Structural requirements for the occupancy of pituitary adenylate cyclase-activating polypeptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP (6-38) as a potent antagonist. Eur. J. Biochem. 207, 239-246.
24. Rostene W. H. (1984) Neurobiological and neuroendocrine functions of the vasoactive intestinal peptide (VIP). Prog. Neurobiol. 22, 103-119.
25. Said S. and Mutt V. (1972) Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon. Eur. J. Biochem. 28, 199-204.
26. Salomon Y., Londos C., and Rodbell M. (1974) A highly sensitive adenylate cyclase assay. Anal. Biochem. 58, 541-548.
27. Sherwood N. M., Krueckl S. L., and McRory J. E. (2000) The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr. Rev. 21, 619-670.
28. Shimizu H., Daly J. W., and Creveling C. R. (1969) A radioisotopic method for measuring the formation of adenosine 3′,5′-cycle monophosphate in incubated slices of brain. J. Neurochem. 16, 1609-1619.
29. Vaudry D., Gonzalez B. J., Basile M., Yon L., Fournier A., and Vaudry H. (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev. 52, 269-324.
30. Waelbroeck M., Robberecht P., Coy D. H., Camus J. C., De Neef P., and Christophe J. (1985) Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Endocrinology 116, 2643-2649.
31. You S., Hsu C. C., Kim H., Kho Y., Choi Y. J., El Halawani M. E., Farris J., and Foster D. N. (2001) Molecular cloning and expression analysis of the turkey vasoactive intestinal peptide receptor. Gen. Comp. Endocrinol. 124, 53-65.
32. Zawilska J. B., Niewiadomski P., and Nowak J. Z. (2003) Characterization of vasoactive intestinal peptide/ pituitary adenylate cyclase-activating polypeptide receptors in chick cerebral cortex. J. Mol. Neurosci. 20, 77-85.